[Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology].
BACKGROUND
Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents with JIA. Standardisation of care offers the chance to improve the quality of care of those patients. New studies have been published after completion of our last treatment guideline (2007). An updated consensus process is mandatory.


METHODS
A systematic literature analysis in PUBMED (key words: juvenile idiopathic (rheumatoid) arthritis, therapy; limits: humans, published in the last 3 years, all child 0-18 years, clinical trial) revealed 17 relevant studies. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition were excluded. Representatives nominated by scientific societies and organisations were invited to consensus conferences which were hosted by a professional moderator. The following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences were each attended by more than 95% of the nominated representatives. Consensus statements were confirmed by nominal group technique and Delphi method.


CONCLUSIONS
Updated consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).
Zentrum für Kinder- und Jugendmedizin, HELIOS Klinikum Krefeld.
G
G
Dueckers
N
N
Guellac
M
M
Arbogast
G
G
Dannecker
I
I
Foeldvari
M
M
Frosch
G
G
Ganser
A
A
Heiligenhaus
G
G
Horneff
A
A
Illhardt
R
R
Krauspe
B
B
Markus
H
H
Michels
M
M
Schneider
W
W
Singendonk
H
H
Sitter
M
M
Spamer
N
N
Wagner
T
T
Niehues
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D019317:Evidence-Based Medicine; D005858:Germany; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D033183:Interdisciplinary Communication; D009788:Occupational Therapy; D026741:Physical Therapy Modalities
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D001688:Biological Products; D005938:Glucocorticoids; D007166:Immunosuppressive Agents